Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications

Xing Liu¹, Fen-Fen Yu², Yi-Min Zhong¹, Xin-Xing Guo¹, Zhen Mao¹

¹Department of Glaucoma, The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong 510060, China
²Department of Ophthalmology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

Xing Liu and Fen-Fen Yu contributed equally to this work.

Abstract

Background: Long-term use of benzalkonium chloride (BAC)-preserved drugs is often associated with ocular surface toxicity. Ocular surface symptoms had a substantial impact on the glaucoma patients’ quality of life and compliance. This study aimed to investigate the effects of sodium hyaluronate (SH) on ocular surface toxicity induced by BAC-preserved anti-glaucoma medications treatment.

Methods: Fifty-eight patients (101 eyes), who received topical BAC-preserved anti-glaucoma medications treatment and met the severe dry eye criteria, were included in the analysis. All patients were maintained the original topical anti-glaucoma treatment. In the SH-treated group (56 eyes), unpreserved 0.3% SH eye drops were administered with 3 times daily for 90 days. In the control group (55 eyes), phosphate-buffered saline were administered with 3 times daily for 90 days. Ocular Surface Disease Index (OSDI) questionnaire, break-up time (BUT) test, corneal fluorescein staining, corneal and conjunctival rose Bengal staining, Schirmer test, and conjunctiva impression cytology were performed sequentially on days 0 and 91.

Results: Compared with the control group, SH-treated group showed decrease in OSDI scores (Kruskal-Wallis test: $H = 38.668, P < 0.001$), fluorescein and rose Bengal scores (Wilcoxon signed-ranks test: $z = -3.843, P < 0.001$, and $z = -3.508, P < 0.001$, respectively), increase in tear film BUT ($t$-test: $t = -10.994, P < 0.001$) and aqueous tear production ($t$-test: $t = -10.328, P < 0.001$) on day 91. The goblet cell density was increased ($t$-test: $t = -9.981, P < 0.001$), and the morphology of the conjunctival epithelium were also improved after SH treatment.

Conclusions: SH significantly improved both symptoms and signs of ocular surface damage in patients with BAC-preserved anti-glaucoma medications treatment. SH could be proposed as a new attempt to reduce ocular surface toxicity, and alleviate symptoms of ocular surface damage in BAC-preserved anti-glaucoma medications treatment.

Key words: Anti-glaucoma Medications; Benzalkonium Chloride; Ocular Surface Toxicity; Sodium Hyaluronate

Introduction

Topical anti-glaucoma medication is the most common treatment modality for glaucoma. Long-term use of these preserved eye drops is often associated with ocular surface toxicity, such as dry eye, allergic reactions, and subconjunctival fibrosis. Benzalkonium chloride (BAC), the most commonly used preservative in anti-glaucoma eye drops, is largely responsible for the toxicity.[1-3] Prevalence of ocular surface symptoms was found to be very high in glaucoma patients using preserved drops. Pooled data from 9658 glaucoma patients in several European countries showed that the incidence of ocular surface symptoms ranged between 30% and 50%.[4] Likewise, in the United States, a cross-sectional study demonstrated that 59% of glaucoma patients...
patients reported dry eye symptoms, 61% of patients with decreased tear production, 78% of patients with decreased tear break-up time (BUT).[5] Dry eye symptoms occurred more frequently in severe glaucoma patients when three or more anti-glaucoma medications were used and increased with the duration of glaucoma disease.[6] Multiple studies concluded that ocular surface symptoms had a substantial impact on the glaucoma patients’ quality of life and compliance and became a common reason noted by physicians for switching medications.[7] Meanwhile, ocular surface damage induced by BAC-preserved anti-glaucoma medication was associated with a lower filtration surgery success rate.[8] Unstable tear film and reduction in the production of mucin stimulate the inflammation cascade of the ocular surface epithelial cells.[9] This vicious cycle lead to the occurrence of dry eye disease and the development of subconjunctival fibrosis.[10] Hence, ocular surface symptom induced by BAC-preserved medications should not be ignored in the long-term treatment of glaucoma.

As a widely used artificial tear, sodium hyaluronate (SH) displays excellent effect in dry eye treatment.[11] Furthermore, several in vitro studies showed that SH significantly reduces BAC-induced cytotoxic effects.[12,13] We recently showed that topical application of SH significantly decreased the ocular surface toxicity, such as damages in the superficial structure and integrity, increasing inflammation and apoptosis rate, and reduction of aqueous tear production, induced by BAC-preserved latanoprost in rabbits.[14] However, these results in animal models cannot reflect the whole ocular surface reactions in glaucoma patients, including subjective symptoms and tear film BUT. The purpose of this study was to investigate the therapeutic effects of SH on ocular surface damage induced by long-term BAC-preserved anti-glaucoma medications treatment in clinical setting.

**Methods**

**Study population**

Fifty-eight patients diagnosed with primary open angle glaucoma (POAG), normal tension glaucoma (NTG), or ocular hypertension (OH) were enrolled between February 2013 and June 2014 from the Department of Glaucoma, Zhongshan Ophthalmic Center, Sun Yat-sen University, China. The research adhered to the tenets of the Declaration of Helsinki. The Institutional Review Board had approved the protocol prospectively. Informed consent had been obtained from all the participants. All patients have received long-term topical BAC-preserved anti-glaucoma medications treatment and met the severe dry eye criteria according to the ODISSEY European Consensus Group algorithm.[15] The criteria for diagnosis of severe dry eye disease were as follows: (a) Ocular Surface Disease Index (OSDI) ≥33 and corneal fluorescein staining (CFS) score ≥3; (b) OSDI <33 and CFS ≥3, additional criteria ≥1 or impaired corneal sensitivity; (c) OSDI ≥33 and CFS = 2, additional criteria ≥1; (d) OSDI ≥3 and CFS ≤1, additional criteria ≥1 and BUT <3 s.

Exclusion criteria were as follows: Any ocular surgery treatment, any ≥2 weeks topical eye drops treatment other than anti-glaucoma medications, any lacrimal apparatus and ocular surface diseases, use of contact lenses, any medical treatment that influence tear production, such as dopamine, amitriptyline, estazolam, and immunosuppressive agent, not completing the follow-up protocol.

Fifty-eight patients (101 eyes) were included in the analysis. All patients were maintained the original topical anti-glaucoma treatment. Commercially available unpreserved 0.3% SH (Hialid; Santen, Osaka, Japan) eye drops were administered with 3 times daily for 3 months in the SH-treated group (30 patients, 56 eyes). Control group (28 patients, 55 eyes) were administered by 50 μl phosphate-buffered saline (PBS) 3 times daily for 3 months. PBS and 0.3% SH solutions were administrated in the same container. Patients did not know the ingredients. The interval between SH/PBS and anti-glaucoma medications instillation were at least 1 h.

A follow-up observation of 90 days was performed. All patients underwent the ophthalmologic routine evaluation including best-corrected visual acuity, slit-lamp examination, intraocular pressure measurement and fundus examination on days 0 and 91. OSDI questionnaire, BUT test, CFS, corneal, and conjunctival rose Bengal staining, Schirmer test, and conjunctiva impression cytology were performed sequentially following the methods described below on days 0 and 91. The interval between these examinations and topical treatments were 1 h.

**Ocular Surface Disease Index questionnaire**

The OSDI is a validated, self-administered instrument for assessing the presence and severity of ocular surface disease symptoms.[16] The OSDI questionnaire includes 12 questions about the respondent’s past-week experience with ocular symptoms, vision related function, and environmental triggers.[17] The total OSDI score ranged from 0 to 100. The scores classified ≤12 as normal, 13–22 as mild, 23–32 as moderate, ≥33 as severe.[18]

**Tear film break-up time**

The BUT was measured by applying a slightly moistened fluorescein strip (Tianjin Jingming New Technology Development Co., Ltd., Tianjin, China) to the bulbar conjunctiva and asking the patient to blink. The tear film was then scanned under a slit-lamp with a cobalt filter while the patient refrains from blinking. The time that elapses before the first dry spot appears in the corneal fluorescein layer is the tear film BUT. Normally, the BUT is over 15 s.

**Fluorescein and rose Bengal staining**

Meanwhile, fluorescein will stain the eroded and denuded areas of the corneal epithelium. The scores were graded under a slit-lamp microscope with a cobalt blue filter. Three corneal areas were considered, the area of positive corneal staining was scored from 0 (absent) to 3 (diffuse loss of epithelium).[19]
Thirty minutes later, the disappearance of fluorescein staining was observed under a slit-lamp microscope. Two microliter of 1% rose Bengal was instilled into the conjunctival sac. The dye will stain all eroded and denuded areas of the corneal and conjunctival epithelial cells. Fifteen seconds later, the scores were graded according to the van Bijsterveld grading system[20] under a slit-lamp microscope.

**Schirmer test**

After topical application of proparacaine (ALCAINE®; Alcon, Fort Worth, TX, USA), tear production was measured by the Schirmer test using Whatman 41 filter paper strip (Tianjin Jingming New Technology Development Co., Ltd., Tianjin, China). The strip was placed into the mid and temporal thirds of the lower lid, and the wetted length of the strip was read after 5 min, less than 5 mm was abnormal.

**Conjunctival impression cytology**

After topical application of proparacaine, two 3.5 mm × 3.5 mm round nitrocellulose filter paper (Pall Corporation, New York, USA) were applied separately on the superior nasal and superior temporal bulbar conjunctiva, and pressed for 10 s with constant pressure. The specimens were fixed with 95% ethanol and stained with periodic acid-Schiff and hematoxylin. The number of goblet cells was counted under a light microscope (Olympus, Tokyo, Japan) in a masked fashion. Three nonadjacent high power fields (×400) of each specimen were observed randomly for counting; an average was calculated. The morphology of the conjunctival epithelium was graded according to the Nelson’ method.[21]

**Statistical analysis**

Statistical analyses were performed using the SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). Kruskal-Wallis test was applied to make comparisons of fluorescein and rose Bengal staining scores. Wilcoxon signed-ranks test was applied to make comparisons of BUT, aqueous tear production, and conjunctival goblet cell density (GCD). A P < 0.05 was considered statistically significant.

**RESULTS**

**General characteristics**

A total of 58 patients (101 eyes), who were diagnosed with POAG, NTG, or OH, were included in this study. A general characteristic of the patients, the average time of topical anti-glaucoma medications application, and the average number of category of anti-glaucoma drugs were presented in Table 1. The topical anti-glaucoma medications included latanoprost (0.02% BAC), travoprost (0.015% BAC), bimatoprost (0.005% BAC), carteolol (0.005% BAC), brimonidine (0.005% BAC), and brinzolamide (0.01% BAC). No significant difference was found between the two groups in all categories.

**Ocular Surface Disease Index scores**

Before administration of SH or PBS (day 0), no significant difference for symptoms was found between the two groups in the patients’ OSDI scores. There were 36.7% of patients with burning or stinging sensation, 30% of patients with foreign body sensation, 23.3% of patients with dry eye, and 33.3% of patients with blurred vision on day 0. After administration of SH or PBS, the OSDI scores were improved significantly (Kruskal-Wallis test: H = 38.668, P < 0.001) in the SH-treated group, than the control group on day 91. The symptoms were relieved after SH treatment. There were only 20% of patients with burning or stinging sensation, 13.3% of patients with foreign body sensation, 3.3% of patients with dry eye, and 16.7% of patients with blurred vision in the SH-treated group [Table 2].

**Break-up time**

Before administration of SH or PBS (day 0), no significant difference was found between the two groups in the tear film BUT. After administration of SH/PBS, the tear film BUT were prolonged significantly (t-test: t = −10.994, P < 0.001) in the SH-treated group than the control group on day 91.

**Fluorescein and rose Bengal staining**

Before administration of SH or PBS (day 0), no significant difference was found between the two groups in the CFS scores and conjunctival rose Bengal staining scores. After administration of SH/PBS, the staining scores of fluorescein and rose Bengal were decreased significantly (Wilcoxon signed-ranks test: z = −3.843, P < 0.001, and z = −3.508, P < 0.001, respectively) in the SH-treated group than the control group on day 91.

**Aqueous tear production**

Before administration of SH or PBS (day 0), no significant difference was found between the two groups in the average aqueous tear production. After administration of SH/PBS, the

---

**Table 1: General characteristic of the patients with anti-glaucoma drug treatment**

| Characteristics                                           | SH-treated group        | Control group        | P     |
|-----------------------------------------------------------|-------------------------|----------------------|-------|
|                                                           | (30 patients, 56 eyes)  | (28 patients, 55 eyes) |       |
| Age, years, mean ± SD (range)                             | 46.76 ± 3.21 (18–76)    | 42.97 ± 4.06 (20–75) | 0.662 |
| Male/female, n                                           | 21/9                    | 18/10                | 0.407 |
| Diagnosis (POAG/NTG/OH), n                               | 54/2/0                  | 51/2/2               | 0.796 |
| Time of anti-glaucoma treatment, months, mean ± SD (range)| 39.13 ± 7.38 (6–144)    | 35.07 ± 6.67 (8–138) | 0.336 |
| Number of anti-glaucoma drugs, mean ± SD (range)         | 1.43 ± 0.08 (1–3)       | 1.87 ± 0.12 (1–4)    | 0.117 |

SD: Standard deviation; SH: Sodium hyaluronate; POAG: Primary open angle glaucoma; NTG: Normal tension glaucoma; OH: Ocular hypertension.
The OSDI also has the toxicitiy induced by BAC-preserved latanoprost. Our previous animal experiment has demonstrated that topical treatment of dry eye even in Sjögren’s syndrome patients. SH, a widely used tears substitute, showed a good effect in the current study, we observed that the therapeutic effects of SH on ocular surface damage induced by long-term BAC-preserved anti-glaucoma medications treatment for at least 6 months were significantly decreased the ocular surface toxicity induced by BAC-preserved latanoprost. In the current study, we observed that the therapeutic effects of SH on ocular surface damage induced by long-term BAC-preserved anti-glaucoma medications treatment for at least 6 months and were diagnosed as severe dry eye according to the ODISSEY European Consensus Group algorithm. Several patients presented significant ocular damage signs, but symptom severity was relatively mild. We considered that impaired corneal sensitivity played a major role.

The OSDI is one of the most widely used questionnaires. It reliably assesses the severity, natural history, and effect of ocular surface diseases. The OSDI also has the necessary psychometric properties to be used as an end point in clinical trials of dry eye disease. Compared to the National Eye Institute Visual Functioning Questionnaire-25 and the McMonnies Dry Eye Questionnaire, the OSDI questionnaire obtains a sensitivity of 60% and specificity of 79%. Our result showed that all subjects receiving BAC-preserved anti-glaucoma drops treatment suffered from symptoms related to the ocular surface. However, SH treatment relieved markedly these symptoms such as burning or stinging sensation, foreign body sensation, dry eye, and blurred vision.

Table 2: Compared results of SH-treated group and Control group

| Items                                      | Day 0 SH-treated group | Day 0 Control group | P | P Day 91 SH-treated group | P Day 91 Control group |
|--------------------------------------------|------------------------|---------------------|---|--------------------------|------------------------|
| Items                                      |                        |                     |   |                          |                        |
| OSID scores, n (%)                         |                        |                     |   |                          |                        |
| Normal                                    | 0 (0)                  | 0 (0)               | 0.745 |                     | 0.754                  |
| Mild                                      | 0 (0)                  | 0 (0)               | 0.754 |                     | 0.754                  |
| Moderate                                  | 21 (70.0)              | 22 (78.6)           | 0.001 |                     | 0.001                  |
| Severe                                    | 9 (30.0)               | 5 (17.9)            | 0.001 |                     | 0.001                  |
| BUT (s), mean ± SD (range)                | 5.18 ± 0.38 (3–11)     | 4.69 ± 0.78 (2–10)  | 0.305 |                     | 0.001                  |
| Fluorescein staining scores, median (P<sub>25</sub>–P<sub>75</sub>) | 5 (3–6)               | 5 (3–7)             | 0.918 |                     | 0.001                  |
| Rose Bengal staining scores, median (P<sub>25</sub>–P<sub>75</sub>) | 3 (2–5)               | 3 (2–6)             | 0.877 |                     | 0.001                  |
| Aqueous tear production, mm, mean ± SD (range) | 3.27 ± 0.32 (1–11) | 3.76 ± 0.57 (2–10)  | 0.684 |                     | 0.001                  |
| GCD (HP), mean ± SD (range)               | 29.30 ± 3.15 (5–79)    | 32.66 ± 4.09 (11–68)| 0.667 |                     | 0.001                  |

SD: standard deviation; P<sub>25</sub>–P<sub>75</sub>: Lower quartile – upper quartile; SH: Sodium hyaluronate; OSID: Ocular Surface Disease Index; BUT: Break-up time test; GCD: Goblet cell density.

**DISCUSSION**

Numerous experimental and clinical studies showed that BAC, the most frequently used preservative of topical anti-glaucoma medications, may induce ocular discomfort, tear film instability, superficial structure and integrity impairment, conjunctival inflammation, subconjunctival fibrosis, and epithelial apoptosis. These ocular surface damages affect the patients’ quality of life and treatment compliance and become the potential risk of failure for filtration surgery. Therefore, improvement of the ocular surface and reduction of inflammation prior to surgery should be considered. SH, a widely used tears substitute, showed a good effect in the treatment of dry eye even in Sjögren’s syndrome patients. Our previous animal experiment has demonstrated that topical application of SH significantly decreased the ocular surface toxicity induced by BAC-preserved latanoprost. In the current study, we observed that the therapeutic effects of SH on ocular surface damage induced by long-term BAC-preserved anti-glaucoma medications treatment in clinical setting. All participants were received BAC-preserved anti-glaucoma medications treatment for at least 6 months and were diagnosed as severe dry eye according to the ODISSEY European Consensus Group algorithm. Several patients presented significant ocular damage signs, but symptom severity was relatively mild. We considered that impaired corneal sensitivity played a major role.
Alves et al.\textsuperscript{[28]} compared signs, symptoms and predictive tools used to diagnose dry eye disease in six different systemic well-defined and nonoverlapping diseases (i.e., Sjögren’s syndrome, graft versus host disease, Graves orbitopathy, facial palsy, diabetes mellitus, and glaucoma who received BAC-preserved topical drugs treatment), and found that the best combination of diagnostic tests for dry eye disease were OSDL, BUT and Schirmer test (sensitivity 100%, specificity 95% and accuracy 99.3%). The Schirmer is a screening test for assessment of tear production. Schirmer test with topical anesthesia measure the function of the accessory lacrimal glands (the basic secretors). Measurement of the tear film BUT could sometimes be useful to estimate the mucin content of tear fluid. Deficiency in mucin may not affect the Schirmer test result, but may lead to instability of the tear film. BAC-preserved drugs induce damages in the accessory lacrimal gland cells and mucin-secretion cells, and lead to the deficiency of aqueous layer and mucus layer of tear film. Transmission electron microscopy of the anterior corneal surface demonstrated fixation of the mucus layer after exposure to 0.01% BAC for 5 min, whereas more prolonged exposure (60 min) to 0.01% BAC destroyed the mucus layer.\textsuperscript{[29]} In addition, as a tensioactive compound, BAC is also a detergent for the lipid layer of the tear film, causing evaporation of the aqueous tear film.\textsuperscript{[30]} SH is a linear polymer built from repeating disaccharide units containing N-acetylglucosamine and glucuronic acid.\textsuperscript{[30]} Disaccharides are hydrophilic molecules that confer to SH an excellent water holding capacity. Indeed, SH can incorporate a volume of water approximately more than 1000-fold its initial volume, constituting a viscous polymer.\textsuperscript{[30,31]} This property plays a major role in increasing tear film stability, reducing the evaporation rate of the tear, and long resident-time on the ocular surface.

Fluorescein staining means the disruption of the corneal epithelial cell to cell junctions and damage of corneal epithelial cells.\textsuperscript{[32]} Rose Bengal staining was apparent earlier than fluorescein staining. Rose Bengal stain live and dead epithelial cells that are not adequately protected by the tear film.\textsuperscript{[33]} Besides have damaging effects indirectly on the corneal and conjunctival epithelial cells by breakage of tear film, BAC can damage directly the corneal and conjunctival epithelial cells by biological interaction with proteins, lipids and G proteins in cell membranes.\textsuperscript{[34]} In this study, we observed that SH treatment significantly improved ocular surface staining of patients. We also demonstrated in the earlier animal research that SH could protect ultrastructures such as microvilli on the epithelial cells under the scanning and transmission electron microscopy.\textsuperscript{[14]} As a viscous biopolymer with negative charges, SH can neutralize the toxic cationic charge of the remaining BAC quaternary ammonium in conjunctival sac.\textsuperscript{[13]} Moreover, CD44, a transmembrane receptor linked to the actin cytoskeleton, express in human cornea.\textsuperscript{[35]} It binds to hyaluronate and is also capable of binding fibronectin, laminin, and collagen I. SH promoted human cornea epithelial cells migration and wound healing by the adhesion between CD44, which coats the surface of the denuded areas.\textsuperscript{[36]}

GCD is a pivotal parameter that reflects the overall health of the ocular surface.\textsuperscript{[37]} We used conjunctival impression cytology, the most effective noninvasive technique for counting goblet cells, to evaluate the morphology of the ocular surface. Our study further supports existing data. BAC induced a direct toxicity on goblet cells and inhibited mucin production in goblet cells.\textsuperscript{[14,38]} Reductions of mucin production speed up the damage of tear film stability, thereby aggravating the ocular surface damage and stimulating the inflammation cascade of epithelial cells. The inflammatory immune environment caused apoptosis of goblet cells. Ultimately, this results in a vicious cycle of ocular surface damage.\textsuperscript{[9,14]} Our results showed that SH treatment significantly improved GCD and conjunctival squamous metaplasia of glaucoma patients. Brignole et al.\textsuperscript{[39]} found that SH treatment may decrease expression of apoptosis related inflammatory markers, including Fas, apoptosis 2.7, human leukocyte antigen-DR and CD40 through CD44 mediation in patients with moderate dry eye syndrome and superficial keratitis. SH possibly maintain GCD and stimulates mucin synthesis through its anti-oxidative and anti-inflammatory properties, and help the ocular epithelium damage break out of the vicious cycle.

As far as we known, this research demonstrated firstly the function of SH to decrease the toxicity induced by BAC-preserved anti-glaucoma drops in clinical setting. A limitation of this study was a lack of detecting the alteration of inflammatory cytokines expression and apoptosis rate. Further studies were limited due to the poor availability of living tissue. What’s more, the impacts on the anti-glaucoma treatment (e.g., intraocular pressure reducing the value) need to be observed. On the other hand, even we have observed the use of SH had no effect on the single measurement of intraocular pressure, more parameters, such as curve of intraocular pressure, visual field, retinal nerve fiber layer thickness, should be compared.

In conclusion, our findings demonstrated that SH significantly improved both symptoms and signs of ocular surface damage in patients with BAC-preserved anti-glaucoma medications treatment. SH could become a new attempt to reduce ocular surface toxicity, alleviate symptoms of ocular surface damage, and promote the patients’ quality of life in BAC-preserved anti-glaucoma medications treatment.

Financial support and sponsorship
This study was supported by grants from the Guangdong Science and Technology Fund, China (No. 2013J4500019) and the Fundamental Research Funds of the State Key Laboratory of Ophthalmology.

Conflicts of interest
There are no conflicts of interest.

References
1. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F.
Preservatives in eyedrops: The good, the bad and the ugly. Prog Retin Eye Res 2010;29:312-34.
2. Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: An *ex vivo* and *in vitro* study. Invest Ophthalmol Vis Sci 2004;45:1360-8.
3. Baudouin C, Ricancho L, Warnet JM, Brignole F. *In vitro* studies of antiglaucomatosus prostaglandin analogues: Travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 2007;48:4123-8.
4. Jaenen N, Baudouin C, Poulquier P, Manni G, Figuereido A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007;17:341-9.
5. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5.
6. Erb C, Gast U, Schremmer D. German register for glaucoma patients: Comparison of diagnostic tests in distinct well-defined conditions related to dry eye disease. Int Ophthalmol Clin 2009;49:125-61.
7. Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: Changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009;25:145-52.
8. Broadway DC, Grierson I, O’Briin C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994;112:1446-54.
9. Li C, Song Y, Luan S, Wan P, Li N, Tang J, et al. Research on the stability of a rabbit dry eye model induced by topical application of the preservative benzalkonium chloride. PLoS One 2012;7:e33688.
10. Baudouin C, Pisella PJ, Fillacier K, Craven ER, Montecatini-Palmier M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol 2010;4:1253-61.
11. Aragona P, Papa V, Micali A, Santocoono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002;86:181-4.
12. Pauloin T, Dutot M, Warnet JM, Rat P. *In vitro* modulation of preservative toxicity: High molecular weight hyaluronan decreases apoptosis and oxidative stress induced by benzalkonium chloride. Eur J Pharm Sci 2008;34:263-73.
13. Debbasch C, De La Salle SB, Brignole F, Rat P, Warnet JM, Baudouin C. Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells. Invest Ophthalmol Vis Sci 2002;43:3409-15.
14. Yu F, Liu X, Zhong Y, Guo X, Li M, Mao Z, et al. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: An *in vivo* study. Invest Ophthalmol Vis Sci 2013;54:3385-93.
15. Baudouin C, Aragona P, Van Setten G, Rolando M, Irkeç M, Benitez del Castillo J, et al. Diagnosing the severity of dry eye: A clear and practical algorithm. Br J Ophthalmol 2014:98:1168-76.
16. Schiﬀman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000;118:615-21.
17. Ozcura F, Aydin S, Helvaci MR. Ocular Surface Disease Index for the diagnosis of dry eye syndrome. Ocul Immunol Inflamm 2007;15:389-93.
18. Miller KL, Walt JG, Mink DR, Satram-Hoang S, Wilson SE, Perry HD, et al. Minimal clinically important difference for the Ocular Surface Disease Index. Arch Ophthalmol 2010;128:94-101.
19. Bron AJ. Diagnosis of dry eye. Surv Ophthalmol 2001;45 Suppl 2:S221-6.
20. van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol 1969;82:10-4.
21. Nelson JD. Impression cytology. Cornea 1988;7:71-81.
22. Dogan AS, Orhan M, Söylemezoglu F, Irkeç M, Bozkurt B. Effects of topical anti‐glaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Experiment Ophthalmol 2004;32:62-6.
23. Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J Glaucoma 2001;10:237-49.
24. Gedde SJ, Schiﬀman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL, Tube Versus Trabeculectomy Study Group. Three-year follow-up of the tube versus trabeculectomy study. Am J Ophthalmol 2009;148:670-84.
25. Aragona P, Di Stefano G, Ferreri F, Spinella R, Stilo A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in sjögren’s syndrome patients. Br J Ophthalmol 2002;86:879-84.
26. Katz, G, Springs CL, Craven ER, Montecatini-Palmier M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol 2010;4:1253-61.
27. Kasetsuwan N, Satitpitakul V, Chantam Chunlakosol S. Incidence and pattern of dry eye after cataract surgery. PLoS One 2013;8:e78657.
28. Alves M, Reinaich PS, Paula JS, Velasco e Cruz AA, Bachet L, Faustino J, et al. Comparison of diagnostic tests in distinct well-defined conditions related to dry eye disease. PLoS One 2014;9:e97921.
29. Chung SH, Lee SK, Cristol SM, Lee ES, Lee DW, Seo KY, et al. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on preconneal mucin. Mol Vis 2006;12:415-21.
30. Laurent TC, Fraser JR. Hyaluronan. FASEB J 1992;6:2397-404.
31. Toole BP. Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer 2004;4:528-39.
32. Wilson G, Ren H, Laurent J. Corneal epithelial fluorescein staining. J Am Optom Assoc 1995;66:435-41.
33. Tseng SC. Evaluation of the ocular surface in dry-eye conditions. Int Ophthalmol Clin 1994;34:57-69.
34. Patarca R, Rosenzweig JA, Zaniga AA, Fletcher MA. Benzalkonium salts: Effects on G protein-mediated processes and surface membranes. Crit Rev Oncog 2000;11:255-305.
35. Zhu SN, Nölle B, Duncker G. Expression of adhesion molecule CD44 on human corneas. Br J Ophthalmol 1997;81:80-4.
36. Gomes JA, Amankwah R, Powell-Richards A, Dua HS. Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells *in vitro*. Br J Ophthalmol 2004;88:821-5.
37. Kinoshita S, Kiorpes TC, Friend J, Thoft RA. Goblet cell density in ocular surface disease. A better indicator than tear mucin. Arch Ophthalmol 1983;101:1284-7.
38. Xiong C, Chen D, Liu J, Liu B, Li N, Zhou Y, et al. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci 2008;49:1850-6.
39. Brignole F, Pisella PJ, Dupas B, Baeyens V, Baudouin C. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol 2005;243:531-8.